Because BC is one of the most common malignancies and remains one of the most lethal, and few novel therapeutic modalities have been discovered lately for the treatment of BC (e.g., programmed cell death protein 1 (PD-1) inhibitors), it seems very attractive to use the anticancer properties demonstrated at the molecular level and the remarkable low toxicity of natural compounds as additional chemo-preventive and therapeutic options for BC patients. Here, PDCD1 is linked to breast cancer.